Olamkicept induces clinical response in nearly 60% of patients with active UC

Biweekly infusions of olamkicept 600 mg increased the likelihood of clinical response and mucosal healing at 12 weeks in patients with active ulcerative colitis compared with placebo, according to results published in JAMA.“Olamkicept, a first-in-class, selective inhibitor of the s-interleukin-6R/IL-6 complex, is a dimer formed by fusing two complete extracellular domains of gp130 to human IgG1Fc that inhibits IL-6 trans-signaling by binding to and neutralizing the sIL-6R/IL-6 complexes but does not block classic IL-6 signaling,” Shenghong Zhang, MD, of the department ofRead More